Johnson & Johnson-Medivir AB's Drug Works Against Hepatitis C

Published: Oct 23, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Johnson & Johnson (JNJ)’s and Medivir AB (MVIRB)’s experimental hepatitis C treatment is safe and effective, U.S. regulators said, providing a boost to the companies as they try to reach a highly competitive market for new treatments. The drug known as simeprevir helps cure patients of the infectious disease that can lead to a liver transplant, Food and Drug Administration staff said in a review today ahead of an Oct. 24 meeting of agency advisers to discuss the medicine. The FDA is scheduled to decide whether to approve simeprevir for sale by Nov. 27.

Help employers find you! Check out all the jobs and post your resume.

Back to news